Cargando…

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236626/ https://www.ncbi.nlm.nih.gov/pubmed/24458878 http://dx.doi.org/10.1007/s00345-014-1244-2

Ejemplares similares

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
por: Khullar, Vik, et al.
Publicado: (2013)

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
por: Mueller, Elizabeth R., et al.
Publicado: (2019)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
por: Castro-Diaz, D., et al.
Publicado: (2015)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
por: Griebling, Tomas L., et al.
Publicado: (2020)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
por: Igawa, Yasuhiko, et al.
Publicado: (2010)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting
por: Huang, Chiung-Kun, et al.
Publicado: (2020)

β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
por: Zhao, Lin, et al.
Publicado: (2022)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hnf6g41bl0c6fg278a0i7mt2g3